- Digital program available to patients through participating
pharmacies seeks to increase medication adherence -
TORONTO, Nov. 23, 2015 /CNW/ -- Mylan EPD in
Canada – a subsidiary of one of
the world's leading pharmaceutical companies, Mylan N.V. (NASDAQ,
TASE: MYL) – today announced the launch of MyFreshStart™ for
patients taking MAVIK®, an innovative, digital
medication adherence and engagement program for patients who have
been prescribed MAVIK® (trandolapril) in Canada*.
The MyFreshStart™ program, offered to patients through
participating pharmacies, provides tools to help increase compliant
behaviors such as maintaining prescription refills and taking
MAVIK® as prescribed.
Head of Mylan EPD in Canada
Barry Hayter commented: "We're excited to announce the launch of
MyFreshStart™ for pharmacists and their patients. We know that
nonadherence negatively impacts health outcomes, and we believe
this program provides pharmacists with a meaningful platform to
discuss the importance of compliance with their patients. This new
resource reinforces Mylan's commitment to expand access to high
quality medicine as we innovate to meet unmet needs."
Developed with support from U.S.-based HealthPrize Technologies,
LLC, MyFreshStart™ seeks to educate patients about hypertension
(high blood pressure) and how they can better manage it through
engaging activities such as quizzes, daily fortunes, leaderboards
and sweepstakes. Once enrolled in MyFreshStart™ through a
participating pharmacy, patients can access the platform to begin
earning points that can be redeemed for health-related items.
Mylan EPD is offering MyFreshStart™ at no cost to pharmacies,
which serve as the primary provider of patient enrollment for the
program, and looks forward to continue partnering with pharmacists
as key drivers of patient engagement and empowerment. Pharmacists
with questions can contact Mylan's Customer Service at
1-844-596-9526.
Mylan N.V. is a global pharmaceutical company committed to
setting new standards in healthcare. Working together around the
world to provide 7 billion people access to high quality medicine,
we innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of around 1,400 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral
therapies, upon which nearly 50% of HIV/AIDS patients in developing
countries depend. We also operate one of the largest active
pharmaceutical ingredient manufacturers and currently market
products in about 145 countries and territories. Our workforce of
approximately 30,000 people is dedicated to creating better health
for a better world, one person at a time. Learn more at mylan.com
and mylan.ca.
*MyFreshStart is not currently available in Quebec.
MAV-2015-0021
SOURCE Mylan N.V.